● Recruiting

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Condition: Hematologic Malignancies · Sponsor: Asmaa Hassan mohamed Abdel Mawjoud

PhaseN/A

Planned participants38

Who can joinAll sexes, N/A to no upper limit

Healthy volunteersYes

About this study

CD56(cluster of differentiation 56) was found to be ectopically expressed in multiple myeloma . A met analysis indicated that CD56 over expression may be an adverse prognostic factor in AML. To the best of our knowledge, no available data the expression pattern of CD56 in other Hematologic malignancies. This work is designed to evaluate the expression pattern of CD56 in hematologic malignancies.

This description comes directly from the study's public registry record.

Talk to the study team

asmaa H mohamed, R.DR · +201024850070 · a94asmaa@gmail.com

Dina A Mohareb, a.prof · +201062427707 · dinamhreb@icloud.com

Always discuss trial participation with your own doctor first.

Locations (2)

Assiut University	Asyut, Egypt	Completed
Assiut university	Asyut, Egypt	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04546945